Susy Shim

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Morten Bækbo Ladekarl · 3 shared papers, 2023–2025 · strength 0.62
   • Paper ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-p… DOI 10.3389/fonc.2025.1558184↗
   • Paper Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. DOI 10.1016/j.isci.2024.111026↗
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
2. Britta Weber · 2 shared papers, 2023–2025 · strength 0.43
   • Paper ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-p… DOI 10.3389/fonc.2025.1558184↗
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
3. Sönke Detlefsen · 2 shared papers, 2023–2024 · strength 0.36
   • Paper Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. DOI 10.1016/j.isci.2024.111026↗
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
4. Rasmus Virenfeldt Flak · 1 shared paper, 2024 · strength 0.20
   • Paper Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. DOI 10.1016/j.isci.2024.111026↗
5. Mogens Tornby Stender · 1 shared paper, 2024 · strength 0.20
   • Paper Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. DOI 10.1016/j.isci.2024.111026↗
6. Ole Thorlacius‐Ussing · 1 shared paper, 2024 · strength 0.20
   • Paper Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. DOI 10.1016/j.isci.2024.111026↗
7. Louise S. Rasmussen · 1 shared paper, 2023 · strength 0.16
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
8. Gabor Istvan Liposits · 1 shared paper, 2023 · strength 0.16
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
9. Stine Brændegaard Winther · 1 shared paper, 2023 · strength 0.16
   • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
10. Julia Sidenius Johansen · 1 shared paper, 2023 · strength 0.16
    • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
11. Per Pfeiffer · 1 shared paper, 2023 · strength 0.16
    • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗
12. Inna Markovna Chen · 1 shared paper, 2023 · strength 0.16
    • Paper A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable p… DOI 10.21203/rs.3.rs-2955930/v1↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.